Figure 1.
In Analysis 1, patients were followed for 365 days for the outcomes of interest. In Analysis 2, an ‘episode’ was defined as the time from the admission test until the first of these occurrences: a) 365 days elapsed; b) the patient was readmitted and underwent another surveillance test (and thus potentially re-categorized); c) the patient experienced the outcome of interest. Upon readmission, a new episode began and the patient was re-categorized into Group 1, 2, or 3 according to the results of the new nasal swab.
Table 1.
Baseline Characteristics of Patient Episodes in Analysis 1.
Table 2.
One-Year Risk of MRSA-positive Clinical Culture Stratified by Group and History of MRSA.
Table 3.
One-Year Risk of MRSA-positive Clinical Culture Among Patients with Excellent Follow-up Stratified by Group and History of MRSA.
Table 4.
One-year risk of MRSA-positive Clinical Culture and ‘MRSA-positive Clinical Culture or SSTI Diagnosis’ in Group 1 Patients According to PVL status.
Table 5.
Baseline Characteristics of Patient Episodes in Analysis 2.
Table 6.
Hazard Ratios for Association Between MRSA Nasal Colonization and Future MRSA-positive Clinical Culture in Multivariable Model Subgroup Analyses.
Figure 2.
Kaplan Meier Curve of MRSA-positive Clinical Culture-free Survival Stratified by Group.